New drug combo takes on tough lung cancer
NCT ID NCT07550842
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called BL0020 combined with the immunotherapy Toripalimab in 33 people whose extensive-stage small cell lung cancer has returned after initial treatment. The main goal is to check safety and find the right dose, while also seeing if the combination can shrink tumors. It is an open-label study, meaning everyone gets the active treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL0020 (a drug) combined with Toripalimab (an immunotherapy)
What this could lead to
If it works, this could point toward a new treatment option for people with recurrent extensive-stage small cell lung cancer.
What could go wrong
This is a very early Phase 1 trial with only 33 participants, so it is primarily testing safety. The combination may not shrink tumors or improve survival, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL CARCINOMA OF LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450008, China
-
Shanghai Chest Hospital
Shanghai, 200030, China
-
Shanghai Pulmonary Hospital
Shanghai, 200433, China
-
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, 317000, China
-
The First Hospital of China Medical University
Shenyang, Liaoning, 110001, China
-
The First People's Hospital of Changzhou
Changzhou, Jiangsu, 213003, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China